The document is a transcript of the Q4 FY '26 Earnings Conference Call held on Monday, May 25, 2026, following the announcement of audited financial results for the quarter and financial year ended March 31, 2026.
The event was an earnings call and investor interaction to discuss quarterly results and strategic updates, including recent acquisitions and business performance.
Management participants included Mr. Anand Desai (Managing Director), Mr. Gopal Agrawal (Chief Executive Officer), Mr. Amit Khurana (Chief Financial Officer), and Mr. Vishal Thakkar (Deputy Chief Financial Officer).
The transcript is hosted on the company's website at www.anupamrasayan.com, and in case of discrepancy, the audio recordings uploaded on the stock exchange on May 25, 2026, will prevail.
The company did not explicitly state that no unpublished price sensitive information (UPSI) would be shared, but the transcript is a post-event disclosure of the earnings call.
Financial Highlights and Strategic Updates
FY26 Financial Performance (Consolidated, including Tanfac and 1 month 2 days of Jayhawk): Revenue from operations was INR 2,384 crores (up 65% YoY), EBITDA was INR 543 crores (margin 23%), PAT was INR 222 crores (margin 9%).
Q4 FY26 Financial Performance: Total income was INR 639 crores (up 26% YoY), EBITDA was INR 141 crores (margin 22%), PAT was INR 56 crores (margin 9%).
Business Vertical Revenue (Stand-alone FY26): Agrochemicals 55%, Pharma 20%, Performance Materials 18%, Personal Care 7%.
Acquisitions: The company entered a definitive agreement to acquire 43.3-48.2% equity stake in Bliss GVS Pharma, along with an open offer for up to 26% additional shares. The transaction will be funded through INR 300 crores via NCDs and non-voting equity instruments.
Operational Highlights: Operating cash flow was INR 334 crores in FY26. Capex of INR 315 crores was completed, and no major capex is planned in the near term. Working capital improved, with expectations of further improvement in FY27.
Growth Drivers: The company highlighted diversification into pharma and performance materials, with pharma revenue growing 15-fold from INR 21 crores in FY22 to INR 339 crores in FY26. The acquisition of Jayhawk Fine Chemicals provides a U.S. manufacturing footprint and access to defense and semiconductor sectors.
Pro Forma Revenue: Including Anupam (INR 1,676 crores), Tanfac (INR 711 crores), Jayhawk (INR 722 crores), and Bliss (INR 927 crores), the combined entity would have over INR 4,000 crores in revenue and EBITDA of INR 834 crores.
Additional Notes Section
The document includes the full transcript of the earnings call, covering management presentations and Q&A sessions with analysts and investors.
The transcript was submitted to BSE and NSE as a regulatory disclosure under SEBI LODR Regulations.
No financial data beyond what was disclosed in the earnings call is included in this announcement.
The transcript was edited for factual errors and readability, with audio recordings as the primary reference.
